Jay H Hoofnagle

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. doi request reprint Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection
    Jay H Hoofnagle
    Liver Disease Research Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda 20817, USA
    J Infect Dis 199:1112-20. 2009
  2. ncbi request reprint Peginterferon and ribavirin for chronic hepatitis C
    Jay H Hoofnagle
    Liver Disease Research Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA
    N Engl J Med 355:2444-51. 2006
  3. ncbi request reprint AASLD 2005 Distinguished Service Award to Dr. Leonard B. Seeff
    Jay H Hoofnagle
    Liver Disease Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Hepatology 42:1246-7. 2005
  4. ncbi request reprint Course and outcome of hepatitis C
    Jay H Hoofnagle
    Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Hepatology 36:S21-9. 2002
  5. doi request reprint Reactivation of hepatitis B
    Jay H Hoofnagle
    Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Hepatology 49:S156-65. 2009
  6. ncbi request reprint Management of hepatitis B: summary of a clinical research workshop
    Jay H Hoofnagle
    Liver Disease Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
    Hepatology 45:1056-75. 2007
  7. ncbi request reprint Challenges in therapy of chronic hepatitis B
    Jay H Hoofnagle
    Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Room 9A27, Building 31, 31 Center Drive, Bethesda, MD 20892, USA
    J Hepatol 39:S230-5. 2003
  8. ncbi request reprint Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin
    Jay H Hoofnagle
    Liver Diseases Section, Digestive Diseases Branch, and Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Hepatology 38:66-74. 2003
  9. pmc Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C
    Neal D Freedman
    Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, Maryland 20852, USA
    Gastroenterology 140:1961-9. 2011
  10. pmc S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders
    Jordan J Feld
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892 1800, USA
    Gastroenterology 140:830-9. 2011

Detail Information

Publications68

  1. doi request reprint Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection
    Jay H Hoofnagle
    Liver Disease Research Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda 20817, USA
    J Infect Dis 199:1112-20. 2009
    ..Trial registration. ClinicalTrials.gov identifier: NCT00038974 ...
  2. ncbi request reprint Peginterferon and ribavirin for chronic hepatitis C
    Jay H Hoofnagle
    Liver Disease Research Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA
    N Engl J Med 355:2444-51. 2006
  3. ncbi request reprint AASLD 2005 Distinguished Service Award to Dr. Leonard B. Seeff
    Jay H Hoofnagle
    Liver Disease Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Hepatology 42:1246-7. 2005
  4. ncbi request reprint Course and outcome of hepatitis C
    Jay H Hoofnagle
    Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Hepatology 36:S21-9. 2002
    ..Extra-hepatic manifestations include sicca syndrome, cryoglobulinemia, glomerulonephritis, and porphyria cutanea tarda. Knowledge of the course and outcome of hepatitis C is important in developing approaches to management and therapy...
  5. doi request reprint Reactivation of hepatitis B
    Jay H Hoofnagle
    Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Hepatology 49:S156-65. 2009
    ....
  6. ncbi request reprint Management of hepatitis B: summary of a clinical research workshop
    Jay H Hoofnagle
    Liver Disease Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
    Hepatology 45:1056-75. 2007
    ..Clearly, many basic and clinical research challenges remain in defining optimal means of management of chronic hepatitis B...
  7. ncbi request reprint Challenges in therapy of chronic hepatitis B
    Jay H Hoofnagle
    Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Room 9A27, Building 31, 31 Center Drive, Bethesda, MD 20892, USA
    J Hepatol 39:S230-5. 2003
  8. ncbi request reprint Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin
    Jay H Hoofnagle
    Liver Diseases Section, Digestive Diseases Branch, and Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Hepatology 38:66-74. 2003
    ..Whether these improvements will ultimately result in prevention of progression of hepatitis C requires further study...
  9. pmc Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C
    Neal D Freedman
    Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, Maryland 20852, USA
    Gastroenterology 140:1961-9. 2011
    ..However, its relationship with therapy for hepatitis C virus infection has not been evaluated...
  10. pmc S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders
    Jordan J Feld
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892 1800, USA
    Gastroenterology 140:830-9. 2011
    ..We assessed the effect of SAMe on the kinetics of the early antiviral response and interferon signaling in nonresponders to previous antiviral therapy and investigated the mechanisms involved...
  11. ncbi request reprint Pilot study of interferon gamma for chronic hepatitis C
    Alejandro Soza
    The Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Hepatol 43:67-71. 2005
    ..The aims of this pilot study were to assess the antiviral activity and safety of interferon gamma in chronic hepatitis C...
  12. pmc Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C
    Yaron Rotman
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Gut 63:161-9. 2014
    ..Ribavirin improves treatment response to pegylated-interferon (PEG-IFN) in chronic hepatitis C but the mechanism remains controversial. We studied correlates of response and mechanism of action of ribavirin in treatment of hepatitis C...
  13. ncbi request reprint Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection
    Ponni Perumalswami
    Liver Diseases Branch, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892 1800, USA
    Hepatology 43:780-7. 2006
    ..In conclusion, in this cohort of patients with CHC, steatosis was associated with older age, higher BMI, and higher serum ALT levels but not with the presence of or subsequent progression of fibrosis...
  14. ncbi request reprint The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis
    Glen Lutchman
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892, USA
    Hepatology 46:424-9. 2007
    ....
  15. ncbi request reprint Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement
    Glen Lutchman
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Clin Gastroenterol Hepatol 4:1048-52. 2006
    ..This study was conducted to assess changes in serum levels of selected adipokines and proinflammatory cytokines and to relate these changes to the improved liver histology resulting from pioglitazone therapy for NASH...
  16. ncbi request reprint Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy
    Glen Lutchman
    Liver Diseases Branch, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892 1800, USA
    Gastroenterology 132:1757-66. 2007
    ..We sought to evaluate the mutagenic potential of ribavirin in vivo and to determine if conserved regions of hepatitis C virus (HCV) NS5B are mutated during ribavirin therapy...
  17. pmc Sequence analysis of hepatitis C virus from patients with relapse after a sustained virological response: relapse or reinfection?
    Koji Hara
    Translational Hepatology Unit, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
    J Infect Dis 209:38-45. 2014
    ..Conclusions. Sequence comparisons suggest that reappearance of HCV RNA years after a SVR can be from relapse of the initial viral infection rather than reinfection from a different virus. ..
  18. pmc Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C
    Neal D Freedman
    Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD 20852, USA
    Hepatology 50:1360-9. 2009
    ..47 (0.27-0.85) for 3 or more cups/day (P-trend = 0.0003) versus not drinking. Risk estimates did not vary by treatment assignment or cirrhosis status at baseline. Tea intake was not associated with outcomes...
  19. pmc Hepatic involvement and portal hypertension predict mortality in chronic granulomatous disease
    Jordan J Feld
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland 20892 1800, USA
    Gastroenterology 134:1917-26. 2008
    ..Liver involvement in CGD includes vascular abnormalities, which may lead to noncirrhotic portal hypertension...
  20. pmc Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial
    Tania Mara Welzel
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Hepatology 49:1847-58. 2009
    ..51; P = 0.05) and a strong relationship among African American patients; all 10 with SVR who were genotyped for TYK2 -2256 carried the A variant compared with 68 of 120 (57%) nonresponders (P = 0.006)...
  21. pmc Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner
    Golo Ahlenstiel
    Immunology Section, National Institute for Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 1800, USA
    Gastroenterology 138:325-35.e1-2. 2010
    ....
  22. pmc Discordance among transient elastography, aspartate aminotransferase to platelet ratio index, and histologic assessments of liver fibrosis in patients with chronic hepatitis C
    Naveen Gara
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Clin Gastroenterol Hepatol 11:303-8.e1. 2013
    ..We evaluated discordance among TE, APRI, and histology diagnoses of cirrhosis...
  23. pmc Ribavirin improves early responses to peginterferon through improved interferon signaling
    Jordan J Feld
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892 1800, USA
    Gastroenterology 139:154-62.e4. 2010
    ..We evaluated viral kinetics, serum cytokine expression, and viral mutagenesis during early stages of peginterferon therapy with and without ribavirin...
  24. ncbi request reprint Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C
    Kittichai Promrat
    The Liver Diseases Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Gastroenterology 124:352-60. 2003
    ..The roles of other disease-associated chemokine system polymorphisms have not been evaluated in hepatitis C virus infection...
  25. pmc Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study
    Souvik Sarkar
    Liver Disease Branch, Division of Intramural Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, United States
    J Hepatol 57:946-52. 2012
    ..In the Virahep-C study, patients with hepatitis C virus (HCV) genotype 1 infection were treated with peginterferon alfa-2a and ribavirin for up to 48 weeks while undergoing assessment of viral kinetics and clinical symptoms...
  26. ncbi request reprint Cellular immune responses to the hepatitis B virus polymerase
    Eishiro Mizukoshi
    Liver Diseases Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    J Immunol 173:5863-71. 2004
    ..These newly described HBV polymerase epitopes could be a valuable component of a therapeutic vaccine for a large and ethnically diverse patient population...
  27. pmc An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C
    THOMAS R O'BRIEN
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, United States of America
    PLoS ONE 6:e20904. 2011
    ..Using data from the HALT-C Trial, we developed a model to predict a patient's probability of SVR based on IL28B genotype and clinical variables...
  28. pmc Increased caffeine consumption is associated with reduced hepatic fibrosis
    Apurva A Modi
    Liver Diseases Branch, National Institutes of Diabetes and Digestive and Kidney Diseases NIDDK, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Hepatology 51:201-9. 2010
    ....
  29. ncbi request reprint Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C
    Alejandro Soza
    Liver Diseases Section, Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Hepatology 36:1273-9. 2002
    ....
  30. ncbi request reprint Progression of fibrosis in chronic hepatitis C
    Marc G Ghany
    Liver Diseases Section, Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases NIH, Building 10, Room 9B 06, 10 Center Drive, MSC 1800, Bethesda, MD 20892 1800, USA
    Gastroenterology 124:97-104. 2003
    ..We evaluated a large cohort of patients with chronic hepatitis C (CHC) using liver histology to assess the rate and predictors of progression of fibrosis...
  31. pmc Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression
    Tara N Palmore
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10 Center Drive, MSC 1888, Bethesda, Maryland 20892 1888, USA
    Clin Gastroenterol Hepatol 7:1130-7. 2009
    ..We report 6 patients who experienced loss of serologic markers of hepatitis B immunity and reappearance of HBsAg in the serum as a result of a variety of acquired immune deficiencies...
  32. pmc Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations
    David E Kleiner
    Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD
    Hepatology 59:661-70. 2014
    ....
  33. pmc Important factors in reliable determination of hepatitis C virus genotype by use of the 5' untranslated region
    Koji Hara
    National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Clin Microbiol 51:1485-9. 2013
    ..Sequencing of the HCV 5' UTR provided reliable genotyping results and resolved discrepancies identified in commercial assays, but genotyping by sequencing was highly dependent upon sequence length...
  34. ncbi request reprint Hepatic abnormalities in patients with chronic granulomatous disease
    Nadeem Hussain
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892 1800, USA
    Hepatology 45:675-83. 2007
    ..Vascular lesions such as venopathy and--to a lesser extent--NRH are common. The cause and clinical consequences of venopathy await prospective evaluation...
  35. ncbi request reprint Resolution of chronic hepatitis B-associated autoimmune neutropenia with interferon-alpha therapy
    Alejandro Soza
    Liver Diseases Section, Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Health, Bethesda, Maryland 20892 1800, USA
    J Pediatr Gastroenterol Nutr 36:141-3. 2003
  36. ncbi request reprint A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis
    Kittichai Promrat
    Liver Diseases Section, Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
    Hepatology 39:188-96. 2004
    ..The long-term safety and benefits of pioglitazone require further study...
  37. ncbi request reprint Peds-C
    Jay H Hoofnagle
    Liver Disease Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
    Hepatology 41:421. 2005
  38. ncbi request reprint Mechanism of action of interferon and ribavirin in treatment of hepatitis C
    Jordan J Feld
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Building 31, Room 9A27, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 436:967-72. 2005
    ..To optimize current therapeutic strategies and to develop new therapies, a better understanding of the mechanism of action of IFN and ribavirin will be essential...
  39. ncbi request reprint Hepatitis C and renal disease: an update
    Catherine M Meyers
    Division of Kidney, National Institute of Diabetes and Digestive and Kidney Diseases, The National Institutes of Health, Bethesda, MD 20892, USA
    Am J Kidney Dis 42:631-57. 2003
    ..There are significant needs in both basic and clinical research in the pathogenesis, natural history, prevention, and therapy for hepatitis C in patients with renal disease...
  40. pmc Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy
    Rohit Loomba
    National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, U S Department of Health and Human Services, Bethesda, Maryland 20892, USA
    Ann Intern Med 148:519-28. 2008
    ..Lamivudine is increasingly being used to prevent hepatitis B reactivation in patients with cancer who test positive for hepatitis B surface antigen (HBsAg) and are undergoing chemotherapy...
  41. ncbi request reprint Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002
    Leonard B Seeff
    National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Health, 31A Center Drive, Room 9A27, Building 37, Bethesda, MD 20892, USA
    Clin Liver Dis 7:261-87. 2003
    ....
  42. pmc Temperature rise after peginterferon alfa-2a injection in patients with chronic hepatitis C is associated with virological response and is modulated by IL28B genotype
    Hwalih Han
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, United States
    J Hepatol 59:957-63. 2013
    ..Interferon treatment for chronic hepatitis C is associated with non-specific symptoms including fever. We aimed to determine the association of temperature changes with interferon antiviral activity...
  43. ncbi request reprint National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002
    Leonard B Seeff
    Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Hepatology 36:S1-2. 2002
  44. ncbi request reprint Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection
    Heiner Wedemeyer
    Liver Diseases Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 169:3447-58. 2002
    ..Thus, the defective functions of HCV-specific CD8+ T cells might contribute to viral persistence in chronically infected patients, and knowledge on their reversibility may facilitate the development of immunotherapeutic vaccines...
  45. pmc Evaluation of the patient with hepatitis B
    Yaron Rotman
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases NIDDK, National Institutes of Health NIH, Bethesda, MD, USA
    Hepatology 49:S22-7. 2009
    ..Better biomarkers and imaging modalities are needed for early detection of HCC. Finally, studies are needed to better refine the indications and to balance the risks and benefits of antiviral therapy...
  46. ncbi request reprint After the doubling
    Jay H Hoofnagle
    Liver Disease Research Branch Division of Digestive Diseases and Nutrition National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health, Bethesda, MD, USA
    Hepatology 40:275. 2004
  47. pmc Denying the wolf access to sheep's clothing
    Theo Heller
    Liver Diseases Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Clin Invest 112:319-21. 2003
    ..A new report describes a novel small animal model for HDV replication and demonstrates that prenylation inhibitors are highly effective at clearing viremia and thus have potential relevance for the treatment of chronic delta hepatitis...
  48. ncbi request reprint Biliary Atresia Research Consortium (BARC)
    Jay H Hoofnagle
    Liver Disease Research, NIH, Bethesda, MD, USA
    Hepatology 39:891. 2004
  49. ncbi request reprint Research opportunities on alcohol and liver damage
    Samir Zakhari
    Division of Metabolism and Health Effects NIAAA, National Institutes of Health Bethesda, MD, USA
    Hepatology 42:1243. 2005
  50. ncbi request reprint Hepatitis B
    Jay H Hoofnagle
    Liver Disease Research Branch, NIDDK, National Institutes of Health, Bethesda, MD, USA
    Hepatology 42:748. 2005
  51. ncbi request reprint Liver disease research funding
    Jay H Hoofnagle
    Liver Disease Research Branch Division of Digestive Diseases and Nutrition National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health Bethesda, MD, USA
    Hepatology 39:279. 2004
  52. ncbi request reprint Milk thistle and chronic liver disease
    Jay H Hoofnagle
    NIDDK, NIH, Bethesda, MD, USA
    Hepatology 42:4. 2005
  53. ncbi request reprint Drug-induced liver injury network (DILIN)
    Jay H Hoofnagle
    Liver Disease Research Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
    Hepatology 40:773. 2004
  54. ncbi request reprint Neonatal screening for biliary atresia
    Jay H Hoofnagle
    Liver Disease Research Branch, Division of Digestive Diseases and Nutrition, NIDDK, National Institutes of Health, Bethesda, MD, USA
    Hepatology 43:646. 2006
  55. ncbi request reprint Hepatocellular carcinoma: summary and recommendations
    Jay H Hoofnagle
    Liver Disease Research Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Gastroenterology 127:S319-23. 2004
  56. ncbi request reprint Peginterferon Alfa-2b and ribavirin for 12 versus 24 weeks in HCV infection
    Brian B Borg
    N Engl J Med 353:1182-3; author reply 1182-3. 2005
  57. ncbi request reprint Hepatitis B--preventable and now treatable
    Jay H Hoofnagle
    N Engl J Med 354:1074-6. 2006
  58. pmc Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop
    Raymond T Chung
    Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    Hepatology 47:306-20. 2008
  59. pmc Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection
    Charles D Howell
    University of Maryland Baltimore School of Medicine, Baltimore, Maryland 21201, USA
    Clin Gastroenterol Hepatol 6:575-83. 2008
    ....
  60. ncbi request reprint Optimal therapy of hepatitis C
    Adrian M Di Bisceglie
    Division of Gastroenterology and Hepatology and the Department of Internal Medicine, Saint Louis University School of Medicine, Saint Louis University, St Louis, MO 63110, USA
    Hepatology 36:S121-7. 2002
    ....
  61. ncbi request reprint Race, insulin resistance and hepatic steatosis in chronic hepatitis C
    Hari S Conjeevaram
    Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109 0362, USA
    Hepatology 45:80-7. 2007
    ..32-0.91, P = 0.02). Insulin resistance but not steatosis was associated with a lower rate of sustained virological response when adjusted for known factors that predict response (relative risk 0.87, 95% CI 0.77-0.99, P = 0.028)...
  62. ncbi request reprint Viral kinetics in hepatitis C
    Glen Lutchman
    Hepatology 37:1257-9. 2003
  63. ncbi request reprint Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection
    Robert J Fontana
    Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
    Hepatology 44:925-35. 2006
    ..The excellent performance of the Virahep-C model in an external validation cohort suggests the findings are replicable and potentially generalizable...
  64. ncbi request reprint Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1
    Hari S Conjeevaram
    Division of Gastroenterology, The University of Michigan, Ann Arbor, Michigan 48109 0362, USA
    Gastroenterology 131:470-7. 2006
    ..Compared with Caucasian Americans (CA), African Americans (AA) with chronic hepatitis C are less likely to respond to interferon-based antiviral therapy...
  65. ncbi request reprint Mortality rate during interferon alfa-ribavirin combination therapy of chronic hepatitis C
    Alejandro Soza
    Hepatology 38:267. 2003
  66. ncbi request reprint Primary sclerosing cholangitis: summary of a workshop
    Nicholas F Larusso
    Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA
    Hepatology 44:746-64. 2006
    ..Thus, significant opportunities remain for basic and clinical research into the cause, natural history, and therapy of PSC...
  67. ncbi request reprint New therapies for hepatitis C
    Apurva A Modi
    Hepatology 46:615-7. 2007
  68. ncbi request reprint A framework for management of hepatitis C in prisons
    Anne C Spaulding
    Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Ann Intern Med 144:762-9. 2006
    ....